Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
American Journal of Pharmaceutical Education|December 7, 2006
Effect of students' perceptions of course load on test anxietySujit S Sansgiry, Kavita Sail
American Journal of Pharmaceutical Education|December 7, 2006
Factors that affect academic performance among pharmacy studentsSujit S Sansgiry, Monali Bhosle, Kavita Sail
Ethnicity & Health|November 10, 2011
Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancerKavita Sail, Luisa Franzini, David Lairson, et al.
Leukemia & Lymphoma|July 13, 2011
Economic impact of disease progression in follicular non-Hodgkin lymphomaRoy Beveridge, Sacha Satram-Hoang, Kavita Sail, et al.
Leukemia & Lymphoma|December 11, 2020
Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in IsraelClara Weil, Gabriel Chodick, Varda Shalev, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 28, 2018
The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United StatesPablo Martinez-Martin, Dendy Macaulay, Yash J Jalundhwala, et al.
Journal of Comparative Effectiveness Research|November 23, 2022
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphomaSally D Miller, Greta Lozano-Ortega, Alex Mutebi, et al.
Journal of Medical Economics|September 13, 2017
The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's diseaseJulia Lowin, Kavita Sail, Rakhi Baj, et al.
Pharmacoeconomics - Open|November 5, 2022
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in CanadaAnuja Chatterjee, Gijs van de Wetering, Ron Goeree, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Sheila Shapouri, Beenish S Manzoor, et al.
Pageof 2